Search
Search
#1. 伴隨臨床試驗同步進行藥物經濟研究 - 財團法人醫藥品查驗中心
analysis, CEA)、成本效用分析(cost-utility analysis, CUA)、成本效益分析(cost-benefit ... cost-effectiveness ratio, ICER)進行比較，以ICER 較低者為優先。 ICER=.
#2. 成本效益分析(Cost-benefit analysis)
遞增成本效果比值(ICER)為成本效果分析(CEA)的主要統計指標，用於總結醫療保健 ...
CEA所用的指標稱為Incremental Cost-Effectiveness Ratio (ICER)，假如 ... ICER就像是經濟學中的邊際成本概念，每多出一分的效果時必須多花的成本。
#4. 2017 - 02 - 社團法人台灣藥物經濟暨效果研究學會
最後由Dr. Kim根據他最近發表的概念提出第四點：介紹新的經濟評估的方程式以評估不同政策效益。傳統的經濟評估的方程式如: incremental cost-effectiveness ratio (ICER)是 ...
#5. 遞增成本效益比例(incremental cost-effectiveness ratio - 基因線上
Browsing: QALY)，遞增成本效益比例(incremental cost-effectiveness ratio. 產業動態. 2017 年11 月22 日 0 · 你願意花多少錢買一年的壽命？
#6. 計畫名稱：肺炎鏈球菌感染症之疾病負擔及相關疫苗效益評估
3.1 中文摘要. ... PCV7，兩者成本效益分析顯示ICER 為cost-saving。然而. PCV13 vs. ... 則增加的成本效果比(incremental cost-effectiveness ratio; ICER)，如下 ...
#7. 增量成本效果比(ICER, Incremental cost-effectiveness ratio)
指使用一个新科技而不使用一个旧科技，每多增加一个治疗效果要多花多少治疗成本，用来比较一个新科技和目前已正在使用的标准治疗法(如：糖尿病一个 ...
#8. incremental cost-effectiveness ratio中文 - 數位感
提供incremental cost-effectiveness ratio中文相關PTT/Dcard文章，想要了解更多cost effectiveness中文有關資訊與科技文章或書籍，歡迎來數位感提供您完整相關訊息.
#9. 藥價訂多少不是藥廠說了算? 抗花生過敏新藥市場價值將受限
根據ICER的報告，認為如果要達到付款人最常用的10萬美元QALY的門檻基準，AR101每年的費用約3,500美元，Viaskin則約2,500美元。
#10. 增量成本–效果比_百度百科
增量成本–效果比（incremental cost- effectiveness ratio）是2014年公布的药学名词。 ... 中文名: 增量成本–效果比; 外文名: incremental cost- effectiveness ratio.
#11. 社團法人台灣藥物經濟暨效果研究學會 | 健康跟著走
比值(incremental cost-utility ratio, ICUR)。而成本利益分析 ...,effectiveness ratio, ICER)技術計算其在減少病灶. 再重建上的成本..... 根據增加成本效益比之公式.
#12. Cost Effectiveness Modelling for HTA Ch1 基本概念笔记
Economic Evaluation, Cost Effectiveness Analysis and Health Care Resource ... 上面两图是对增量成本效果比（ICER）和成本效果平面（cost effectiveness plane）的 ...
#13. 財團法人罕見疾病基金會
健保署審查新藥給付，主要是根據「ICER（incremental cost-effectiveness ratio）」，由醫藥品查驗中心參考藥廠提供資料、實證研究報告、各國給付情形提出，而健保專家 ...
#14. Interpreting the Results of Cost-Effectiveness Studies - NCBI
由 DJ Cohen 著作 · 2008 · 被引用 248 次 — CE ratios are often reported as “incremental cost effectiveness ratios” (“iCERs” or “ICERs”), with the “i” emphasizing the notion that CE is not an inherent ...
#15. 美国ACCDON公司旗下品牌 - SCI论文修改
推荐同事 机构合作 中文 繁體中文 English 한국어 日本語 Português Español ... 中英对照. 增量成本–效果比. incremental cost- effectiveness ratio ...
#16. incremental cost翻譯及用法- 英漢詞典 - 漢語網
英漢詞典提供【incremental cost】的詳盡中文翻譯、用法、例句等. ... RESULTS: The cost-effectiveness ratio and incremental cost - effectiveness ratio of ...
#17. Cost-Effectiveness Analysis of Colorectal Cancer Screening
The main outcome measures in this systematic review were the incremental cost-effectiveness ratio (ICER) of screening versus no-screening ...
#18. Cost-Effectiveness of Intensive versus Standard Blood ... - NEJM
BackgroundIn the Systolic Blood Pressure Intervention Trial (SPRINT), adults at high risk for cardiovascular disease who received intensive ...
#19. Re: [討論] 藥事經濟學的專有名詞- 看板Pharmacy
... 字面翻譯「原藥雖然ICER較高但替代藥比較有效」 但是ICER是指達成一個單位治療效果，所需花費的成本(ICER:Incremental cost-effectiveness ratio)
#20. 成本效果阈值 - MBA智库百科
虽然目前并没有达成关于成本效果阈值的统一定义，但成本效果阈值本质上是一个ICER的临界值，是判断项目是否具有经济性(即对资源的利用是否有“效率”)的 ...
#21. Incremental Cost-Effectiveness Ratio (ICER) - YHEC - York ...
An ICER is calculated by dividing the difference in total costs (incremental cost) by the difference in the chosen measure of health outcome or effect ( ...
#22. Incremental cost-effectiveness ratio - Wikipedia
Incremental cost -effectiveness ratio ... are the cost and effect in the control care group. ... Costs are usually described in monetary units, while effects can be ...
#23. Biggest healthcare shifts we'll see in 2022 as per experts
Incremental advances across connected drug delivery, ... reduce hospitalisation and increase healthcare workforce effectiveness.
#24. How banks are reimagining tax and finance functions to ... - EY
Regulatory change, cost pressures, and technology are driving banks to ... decreased cost, agility and operational effectiveness are the new ...
#25. “incremental cost-effectiveness ratio” | GET-IT Glossary MART
The incremental cost-effectiveness ratio (ICER) is a measure of the efficiency of a treatment or “value for money”. It is the difference in cost between the ...
#26. A gene-editing prediction engine with iterative learning cycles ...
The consortium's work centers around CRISPR editing effectiveness and ... services helped us cost-effectively and efficiently navigate them, ...
#27. New Deloitte research highlights increasing business concern ...
20 小時前 — That's up 20 percentage points from a Deloitte survey conducted eight ... Less likely to see cost as an obstacle for sustainability efforts, ...
#28. Cost-effectiveness in Health and Medicine - 第 484 頁 - Google 圖書結果
See incremental cost-effectiveness ratio ICMJE. See International Committee of Medical Journal Editors identification, xxvi of costs, xxvii, ...
#29. Cost-Effectiveness Analysis in Health: A Practical Approach
When comparing mammography to no mammography, the difference in costs, morbidity, and mortality is captured in the incremental costeffectiveness ratio.
#30. Cost-effectiveness in Health and Medicine: Report to the ...
Cost - effectiveness analysis should be distinguished from other closely ... the incremental cost - effectiveness ratio relative to some comparator .
#31. Emergency Medicine E-Book: Clinical Essentials (Expert ...
To numerically compare two strategies, we use the incremental cost-effectiveness ratio (ICER). The ICER represents the incremental change in cost and ...
#32. Evidence-Based Nursing: A Guide to Clinical Practice
The study estimated the incremental cost-effectiveness ratio of carvedilol relative to metoprolol as CDN$8394 per life-year gained.
#33. Global Problems, Smart Solutions: Costs and Benefits
... million 687 3,043 population Annual cost per capita (Int$) 0.31 0.27 Average cost-effectiveness ratio (Int$) 448 87 Incremental cost-effectiveness ratio ...
#34. Incremental cost-effectiveness ratio and incremental net ...
Instead of the incremental cost-effectiveness ratio for which statistical inference is often difficult, the incremental net-health benefit ...
incremental cost-effectiveness ratio中文 在 Re: [討論] 藥事經濟學的專有名詞- 看板Pharmacy 的推薦與評價
※ 引述《stvene (賴)》之銘言：
: 給參考
: ※ 引述《loshihchieh (小傑)》之銘言：
: : 版上各位好:
: : 在下幾天前剛完成藥事經濟學第一次的PBL
: : 但是有些名詞的疑惑還是不很清楚
: : 希望前輩們不吝給予指教
: : 題目大致是這樣的
: : 我們在比較
: : atorvastatin simvastatin rosuvastatin
: : 三種藥物的成本效益分析
: : (D)=an alternative is dominated
: : (less effectiveness and more costly than the alternative)
: 替代藥物被原藥物占優勢，也就是原藥物成本較低效益較高
: 純粹就成本和效益的考量就會選原藥物
: : D*:extended dominance:
: : higher ICER than a more effective treatment alternative
: 如果兩者沒有像上面那樣有某藥既成本比較低效益又比較高
: 那麼就得比ICER
: 這裡字面意思就是原藥雖然ICER較高但替代藥比較有效
: : 想請教 D 以及 D* 切確的意義為何?
: : 查了很多資料但常常有經濟學的字出現
: : 有點難解讀
: : 想請版上高手幫忙
: : 很抱歉在下不會打表格
: : 所以沒辦法把詳盡資料給各位參考
: : 雖然是作業
: : 不過作業已經送出去了
: : 所以放心 不會有幫人做作業的疑慮
: : 只是想滿足求知慾 感謝
: 我想把自己的想法先說出來可以讓人更相信
: 祝順利
關於D*:extended dominance
我一開始也跟版大一樣 照字面翻譯
「原藥雖然ICER較高但替代藥比較有效」
但是ICER是指達成一個單位治療效果，所需花費的成本
(ICER:Incremental cost-effectiveness ratio)
也就是高ICER的藥要達到相同效益所需的錢需要比較多
如果可以翻譯成
「原藥雖然ICER較低但替代藥比較有效」
這樣感覺比較說得通
也就是這句話有矛盾......
之前上網去查 結果跑出一堆經濟學的圖......
看他們解釋半天也不大懂.....
而同學是把這句話直接跳過去...
謝謝stvene大大的熱心回答
--
※ 發信站: 批踢踢實業坊(ptt.cc)
◆ From: 114.38.122.242
... <看更多>